The Discounted Cash Flow (DCF) valuation of Egetis Therapeutics AB (publ) (EGTX.ST) is (716.99) SEK. With the latest stock price at 6.42 SEK, the upside of Egetis Therapeutics AB (publ) based on DCF is -11268.0%.
Based on the latest price of 6.42 SEK and our DCF valuation, Egetis Therapeutics AB (publ) (EGTX.ST) is a sell. selling EGTX.ST stocks now will result in a potential gain of 11268.0%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 5.0% - 8.0% | 6.5% |
| Long-term Growth Rate | 3.0% - 4.8% | 3.9% |
| Fair Price | (7,508.51) - (379.69) | (716.99) |
| Upside | -117055.0% - -6014.2% | -11268.0% |